Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Radioiodine treatment for non-toxic goitre

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Sex differences in acromegaly at diagnosis: A nationwide cohort study and meta-analysis of the literature

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Adrenal insufficiency in kidney transplant patients during low-dose prednisolone therapy: a cross-sectional case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Corticotroph aggressive pituitary tumours and carcinomas frequently harbour ATRX mutations

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

There is no ideal treatment for benign multinodular goitre. Besides surgery, which is recommended for large goitres or when malignancy cannot be excluded, the non-surgical treatment options are levothyroxine therapy and radioiodine ((131)I) therapy. Conventional (131)I therapy [without recombinant human thyroid-stimulating hormone (rhTSH)] has been used for more than a decade in symptomatic non-toxic multinodular goitre, and although it does lead to significant thyroid volume reduction, relatively high activities of radioiodine are needed because of a frequent finding of a low thyroid radioiodine uptake. rhTSH, even when used in very small doses in combination with (131)I therapy, enhances the thyroid volume reduction at lower (131)I activities by doubling the thyroid radioiodine uptake. However, before rhTSH stimulation can be routinely used by clinicians to optimise the (131)I therapy in multinodular goitre, aspects of this association, such as the cost-benefit and optimum rhTSH dose and safety, will have to be sufficiently clarified.

Original languageEnglish
JournalF1000 Medicine Reports
Volume1
ISSN1757-5931
DOIs
Publication statusPublished - 14 Sep 2009

    Research areas

  • Journal Article

ID: 49948075